Fate Therapeutics (FATE) Non-Current Debt (2012 - 2019)
Fate Therapeutics (FATE) posted Non-Current Debt of $9.5 million for Q2 2019, down 13.59% on a QoQ basis from $11.0 million in Q1 2019, and down 26.23% year-over-year from $12.8 million in Q2 2018.
Fate Therapeutics (FATE) Non-Current Debt (2012 - 2019) Analysis & Trends
Fate Therapeutics' Non-Current Debt history runs 8 years deep, the most recent figure standing at $9.5 million for Q2 2019.
- Quarterly Non-Current Debt fell 26.23% year-over-year to $9.5 million in Q2 2019, while the trailing twelve-month figure through Jun 2019 was $9.5 million (down 26.23% YoY) and the FY2018 annual result came in at $12.4 million, down 15.95% from the prior year.
- Non-Current Debt was $9.5 million for Q2 2019 at Fate Therapeutics, down from $11.0 million in the prior quarter.
- Across five years, Non-Current Debt topped out at $16.4 million in Q1 2015 and bottomed at $2.5 million in Q4 2016.
- A 5-year average of $10.7 million and a median of $11.3 million in 2018 frame the typical range for Non-Current Debt.
- Annual changes were most pronounced in 2016 — Non-Current Debt slumped 76.6% — and 2017, when it surged 492.08%.
- Fate Therapeutics' Non-Current Debt stood at $10.7 million in 2015, then slumped by 76.6% to $2.5 million in 2016, then jumped by 492.08% to $14.8 million in 2017, then dropped by 15.95% to $12.4 million in 2018, then fell by 23.92% to $9.5 million in 2019.
- Business Quant data shows FATE's Non-Current Debt at $9.5 million in Q2 2019, $11.0 million in Q1 2019, and $12.4 million in Q4 2018.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | 105.94 Mn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 842.92 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 1.99 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Fate Therapeutics | 288.82 Mn | 288.82 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2019 | 9.47 Mn |
| Mar 31, 2019 | 10.96 Mn |
| Dec 31, 2018 | 12.45 Mn |
| Sep 30, 2018 | 11.60 Mn |
| Jun 30, 2018 | 12.84 Mn |
| Mar 31, 2018 | 14.07 Mn |
| Dec 31, 2017 | 14.81 Mn |
| Sep 30, 2017 | 14.79 Mn |
| Jun 30, 2017 | 6.68 Mn |
| Mar 31, 2017 | 8.75 Mn |
| Dec 31, 2016 | 2.50 Mn |
| Sep 30, 2016 | 4.61 Mn |
| Jun 30, 2016 | 6.68 Mn |
| Mar 31, 2016 | 8.70 Mn |
| Dec 31, 2015 | 10.69 Mn |
| Sep 30, 2015 | 12.64 Mn |
| Jun 30, 2015 | 14.54 Mn |
| Mar 31, 2015 | 16.41 Mn |
| Dec 31, 2014 | 18.07 Mn |
| Sep 30, 2014 | 9.39 Mn |